Endo Gets Surprise Aveed Approval, But REMS Could Be A Roadblock
This article was originally published in The Pink Sheet Daily
Executive Summary
After seven years of rejection, Endo finally gets FDA’s go-ahead on its long-acting testosterone treatment, but a strict REMS program and plenty of market competitors will make the drug’s launch difficult.